ORKA,SYRE,VRDN,ZBIO,COGT,APGE,CBIO Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: KRYS RYTM BMRN VKTX INCY AXSM MDGL ALNY KROS NBIX

| Held by: XBI IWM VTI IWO VXF IBB TCAF SCHA CGMM VTWO

Index	RUT
Market Cap	5.08B
Enterprise Value	4.70B
Income	-116.25M
Sales	0.00M
Book/sh	9.64
Cash/sh	6.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	68
IPO	Aug 08, 1997

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	8.74
P/C	13.07
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	23.76
Current Ratio	23.76
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.39
EPS next Y	-2.51
EPS next Q	-0.51
EPS this Y	-14.20%
EPS next Y	-19.01%
EPS next 5Y	-21.04%
EPS past 3/5Y	34.61% 37.79%
Sales past 3/5Y	- -
EPS Y/Y TTM	54.61%
Sales Y/Y TTM	-
EPS Q/Q	-14.47%
Sales Q/Q	-
Earnings	May 13 AMC
EPS/Sales Surpr.	12.23% -

Insider Own	15.77%
Insider Trans	-28.49%
Inst Own	76.76%
Inst Trans	-0.58%
ROA	-26.37%
ROE	-27.31%
ROIC	-23.83%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.94%
SMA50	19.10%
SMA200	89.89%
Trades

Shs Outstand	60.31M
Shs Float	50.80M
Short Float	18.03%
Short Ratio	5.08
Short Interest	9.16M
52W High	97.78 -13.80%
52W Low	12.84 556.42%
Volatility	5.95% 6.52%
ATR (14)	5.01
RSI (14)	56.72
Beta	-0.31
Rel Volume	0.01
Avg Volume	1.80M
Volume	935

Perf Week	-0.26%
Perf Month	23.10%
Perf Quarter	37.31%
Perf Half Y	202.53%
Perf YTD	178.07%
Perf Year	473.36%
Perf 3Y	546.51%
Perf 5Y	318.57%
Perf 10Y	-76.29%
Recom	1.07
Target Price	143.62
Prev Close	84.56
Price	84.28
Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Piper Sandler	Overweight	$75
Nov-13-25	Initiated	Jefferies	Buy	$45
Oct-27-25	Initiated	Guggenheim	Buy	$60
Oct-13-25	Initiated	Barclays	Overweight	$48
May-22-25	Initiated	BTIG Research	Buy	$44
Feb-04-25	Initiated	Wolfe Research	Outperform	$20
Oct-11-24	Initiated	Stifel	Buy	$49
Oct-07-24	Initiated	H.C. Wainwright	Buy	$45
Sep-17-24	Initiated	Leerink Partners	Outperform	$44
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy	$40
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

Show Previous Ratings

Jul-10-26 07:26PM	HMI Capital Pares Its Stake in AI Company nCino (Barrons.com)
May-28-26 08:00AM	Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-26 04:03PM	Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-26 05:07AM	Halozyme and Oruka sign agreement for Hypercon technology (Pharmaceutical Technology) -8.20%
Apr-28-26 07:42PM	Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering (GlobeNewswire) -7.96%
04:17PM	Loading…
Apr-27-26 04:17PM	Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering (GlobeNewswire) +10.66%
10:24AM	Oruka Therapeutics psoriasis drug clears skin in 64% of patients (Quartz)
09:49AM	Oruka Therapeutics Shares Jump on Strong Psoriasis Trial Results (InvestorsHub)
08:12AM	Oruka surges as long-acting psoriasis drug shows early promise (BioPharma Dive)
07:01AM	How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise (Investor's Business Daily)
07:00AM	Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Apr-26-26 12:00PM	Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 (GlobeNewswire)
Apr-10-26 05:28PM	This Startup's Psoriasis Drug Studies Have Lifted Its Stock (Barrons.com) -6.32%
Mar-12-26 04:05PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.03% +25.04%
Feb-09-26 07:00AM	Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire)
07:00AM	Loading…
Jan-12-26 07:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 (GlobeNewswire) +10.16%
Jan-06-26 07:00AM	Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 04:01PM	Oruka Therapeutics Announces New Board Member and Board Transition (GlobeNewswire)
Nov-12-25 04:05PM	Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.78%
Oct-29-25 09:55AM	Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know (Zacks)
07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Oct-13-25 05:52AM	Barclays initiates coverage on U.S. small & mid-cap biotech stocks (Investing.com)
Sep-29-25 04:24PM	MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment (Investor's Business Daily) +26.91%
Sep-17-25 04:11PM	Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker (Investor's Business Daily) +8.79%
01:02AM	Oruka Therapeutics Announces $180 Million Private Placement (GlobeNewswire)
01:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 (GlobeNewswire)
Aug-11-25 04:04PM	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.90%
Jul-21-25 07:00AM	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September (GlobeNewswire) -5.30%
Jul-01-25 04:01PM	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer (GlobeNewswire) +5.26% +6.86%
May-27-25 03:32PM	H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial (Insider Monkey)
07:00AM	Loading…
May-21-25 07:00AM	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody (GlobeNewswire)
May-14-25 04:15PM	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
Mar-07-25 08:30AM	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-06-25 04:09PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 07:00AM	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire)
Dec-20-24 07:15AM	Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 (TipRanks)
Dec-19-24 07:00AM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire)
Dec-18-24 07:00AM	Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Nov-19-24 08:00AM	Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference (GlobeNewswire) +5.54%
Nov-13-24 04:25PM	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.43%
Nov-04-24 07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Sep-25-24 07:08AM	Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-12-24 07:05AM	Oruka Therapeutics Announces $200 Million Private Placement (GlobeNewswire) -12.22%
07:00AM	Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 (GlobeNewswire)
Sep-03-24 07:00AM	Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million (GlobeNewswire) -11.46%
Aug-29-24 04:50PM	ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split (GlobeNewswire) +33.19%
Aug-26-24 07:30PM	ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) -8.41%
Aug-23-24 04:30PM	ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +6.12%
Aug-16-24 04:15PM	ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +21.36%
Aug-01-24 04:15PM	ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.07%
Jun-28-24 02:16AM	Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)? (Insider Monkey) +6.39%
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey)
May-14-24 01:48PM	3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally (InvestorPlace)
Apr-25-24 09:55PM	ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 (InvestorPlace)
04:15PM	ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire) +5.56%
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.44%
Jul-28-21 08:00AM	Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology (GlobeNewswire)
Jul-13-21 08:00AM	ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire) -14.09%
Jul-09-21 08:00AM	ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th (GlobeNewswire) +5.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) -6.95%
Jul-07-21 08:00AM	ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement (GlobeNewswire) +9.36%

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

PresidentDr. Lawrence Otto Klein Ph.D.

General Counsel & SecretaryMr. Paul T. Quinlan

Chief Medical OfficerDr. Joana Goncalves M.D.

Senior VP of Finance & TreasurerMr. Arjun Agarwal CPA

Chief Operating OfficerMs. Laura Sandler

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agarwal Arjun	Senior Vice President, Finance	Jul 13 '26	Option Exercise	15.69	9,999	156,903	25,311	Jul 13 05:09 PM
Agarwal Arjun	Senior Vice President, Finance	Jul 13 '26	Sale	84.63	9,999	846,180	15,312	Jul 13 05:09 PM
Arjun Agarwal	Officer	Jul 13 '26	Proposed Sale	86.79	28,588	2,481,153		Jul 13 04:36 PM
Fairmount Healthcare Fund II L	Director, 10% Stockholder	Jul 01 '26	Proposed Sale	84.43	3,553,410	300,014,406		Jul 01 09:31 PM
Fairmount Funds Management LLC	Director	Jul 01 '26	Sale	84.43	3,553,410	300,014,406	1,131,954	Jul 01 09:30 PM
Sandler Laura Lee	Chief Operating Officer	Jul 01 '26	Option Exercise	7.80	5,000	39,000	241,384	Jul 01 07:58 PM
Sandler Laura Lee	Chief Operating Officer	Jul 01 '26	Sale	94.42	5,000	472,079	236,384	Jul 01 07:58 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 22 '26	Sale	80.95	1,587	128,468	15,312	Jun 22 07:59 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 12 '26	Option Exercise	15.88	9,459	150,175	26,753	Jun 15 06:57 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 12 '26	Sale	69.72	9,459	659,508	17,294	Jun 15 06:57 PM
Agarwal Arjun	Senior Vice President, Finance	Jun 15 '26	Sale	69.69	395	27,528	16,899	Jun 15 06:57 PM
Goncalves Joana	Chief Medical Officer	Jun 15 '26	Option Exercise	7.32	7,000	51,240	40,665	Jun 15 06:54 PM
Goncalves Joana	Chief Medical Officer	Jun 15 '26	Sale	69.28	7,947	550,607	32,718	Jun 15 06:54 PM
Klein Lawrence Otto	Chief Executive Officer	Jun 15 '26	Sale	69.69	1,729	120,494	925,580	Jun 15 06:52 PM
Sandler Laura Lee	Chief Operating Officer	Jun 15 '26	Sale	69.69	600	41,814	236,384	Jun 15 06:51 PM
Quinlan Paul T	General Counsel	Jun 15 '26	Sale	69.69	733	51,083	31,034	Jun 15 06:50 PM
Dambkowski Carl	Director	Jun 11 '26	Sale	70.13	22,417	1,572,201	51,326	Jun 12 04:36 PM
Dambkowski Carl	Director	Jun 12 '26	Sale	70.11	12,583	882,182	38,743	Jun 12 04:36 PM
CARL DAMBKOWSKI	Director	Jun 11 '26	Proposed Sale	64.03	35,000	2,241,050		Jun 11 04:24 PM
Dambkowski Carl	Director	May 21 '26	Option Exercise	7.95	62,260	494,805	178,743	May 22 04:54 PM
Dambkowski Carl	Director	May 21 '26	Sale	58.97	105,000	6,191,366	73,743	May 22 04:54 PM
CARL DAMBKOWSKI	Director	May 21 '26	Proposed Sale	60.67	105,000	6,370,350		May 21 04:32 PM
Agarwal Arjun	Senior Vice President, Finance	May 18 '26	Option Exercise	28.80	7,833	225,597	26,696	May 18 06:07 PM
Agarwal Arjun	Senior Vice President, Finance	May 18 '26	Sale	59.07	10,290	607,806	16,406	May 18 06:07 PM
ARJUN AGARWAL	Officer	May 18 '26	Proposed Sale	61.93	22,206	1,375,218		May 18 04:34 PM
Goncalves Joana	Chief Medical Officer	May 15 '26	Option Exercise	7.32	7,000	51,240	40,377	May 15 08:17 PM
Goncalves Joana	Chief Medical Officer	May 15 '26	Sale	61.85	7,000	432,935	33,377	May 15 08:17 PM
Sandler Laura Lee	Chief Operating Officer	May 01 '26	Option Exercise	7.80	5,000	39,000	241,984	May 01 06:25 PM
Sandler Laura Lee	Chief Operating Officer	May 01 '26	Sale	63.88	5,000	319,384	236,984	May 01 06:25 PM
LAURA SANDLER	Officer	May 01 '26	Proposed Sale	68.41	10,000	684,100		May 01 04:42 PM
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Option Exercise	7.32	7,000	51,240	40,377	Apr 15 06:45 PM
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Sale	66.12	7,000	462,830	33,377	Apr 15 06:45 PM
JOANA GONCALVES	Officer	Apr 15 '26	Proposed Sale	67.06	21,000	1,408,260		Apr 15 04:54 PM
Klein Lawrence Otto	Chief Executive Officer	Mar 16 '26	Sale	41.30	1,729	71,408	927,309	Mar 17 04:10 PM
Agarwal Arjun	Senior Vice President, Finance	Mar 16 '26	Sale	41.30	395	16,313	18,863	Mar 17 04:09 PM
Sandler Laura Lee	Chief Operating Officer	Mar 16 '26	Sale	41.30	600	24,780	236,984	Mar 17 04:08 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Option Exercise	7.32	7,000	51,240	41,018	Mar 17 04:06 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Sale	40.91	7,641	312,560	33,377	Mar 17 04:06 PM
Quinlan Paul T	General Counsel	Mar 16 '26	Sale	41.30	733	30,273	31,767	Mar 17 04:04 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Option Exercise	7.80	5,000	39,000	242,584	Mar 02 06:47 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Sale	33.56	5,000	167,822	237,584	Mar 02 06:47 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Option Exercise	7.32	7,000	51,240	41,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Sale	32.37	7,000	226,559	34,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Option Exercise	7.32	7,000	51,240	8,518	Jan 16 05:26 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Sale	31.81	7,000	222,704	1,518	Jan 16 05:26 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Option Exercise	7.80	5,000	39,000	218,084	Jan 02 08:25 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Sale	28.52	13,000	370,795	205,084	Jan 02 08:25 PM
LAURA SANDLER	Officer	Jan 02 '26	Proposed Sale	30.31	18,000	545,580		Jan 02 04:31 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Option Exercise	7.32	7,000	51,240	8,518	Dec 19 05:38 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Sale	30.61	7,000	214,293	1,518	Dec 19 05:38 PM
JOANA GONCALVES	Officer	Dec 19 '25	Proposed Sale	28.15	28,000	788,200		Dec 19 04:20 PM

SYRE Spyre Therapeutics Inc daily Stock Chart

Peers: BMRN RYTM APGE KRYS KYMR NUVL AXSM MDGL VKTX NBIX

| Held by: IWM VTI XBI IWO VXF IBB SCHA VTWO VHT CGMM

Index	RUT
Market Cap	8.16B
Enterprise Value	7.58B
Income	-168.74M
Sales	0.00M
Book/sh	6.53
Cash/sh	8.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	102
IPO	Apr 07, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	14.39
P/C	11.01
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.97
Current Ratio	8.97
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.36
EPS next Y	-3.21
EPS next Q	-0.76
EPS this Y	-52.10%
EPS next Y	-6.56%
EPS next 5Y	-23.61%
EPS past 3/5Y	57.01% 44.61%
Sales past 3/5Y	- -
EPS Y/Y TTM	22.31%
Sales Y/Y TTM	-
EPS Q/Q	-46.71%
Sales Q/Q	-
Earnings	May 05 BMO
EPS/Sales Surpr.	-11.18% -

Insider Own	10.82%
Insider Trans	-34.87%
Inst Own	82.69%
Inst Trans	-3.65%
ROA	-25.30%
ROE	-29.26%
ROIC	-25.15%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.29%
SMA50	16.67%
SMA200	100.01%
Trades

Shs Outstand	78.84M
Shs Float	77.45M
Short Float	17.61%
Short Ratio	9.65
Short Interest	13.64M
52W High	102.06 -7.90%
52W Low	14.51 548.05%
Volatility	5.67% 5.73%
ATR (14)	5.21
RSI (14)	58.94
Beta	3.04
Rel Volume	0.00
Avg Volume	1.41M
Volume	244

Perf Week	-0.24%
Perf Month	16.38%
Perf Quarter	48.57%
Perf Half Y	207.09%
Perf YTD	186.94%
Perf Year	472.82%
Perf 3Y	572.63%
Perf 5Y	-46.36%
Perf 10Y	-19.14%
Recom	1.06
Target Price	103.93
Prev Close	93.73
Price	94.00
Change	0.29%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Initiated	Raymond James	Strong Buy	$80
Dec-18-25	Initiated	Mizuho	Outperform	$53
Dec-17-25	Initiated	Citigroup	Buy	$64
Sep-26-25	Initiated	Deutsche Bank	Buy	$43
Apr-08-25	Initiated	Leerink Partners	Outperform	$45
Mar-18-25	Initiated	Wolfe Research	Outperform	$27
Sep-04-24	Initiated	Wedbush	Outperform	$45
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform	$50
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$12 → $35
Dec-20-23	Initiated	BTIG Research	Buy	$32
Dec-11-23	Initiated	Jefferies	Buy	$31
Dec-11-23	Initiated	Guggenheim	Buy	$44
May-04-20	Initiated	Piper Sandler	Overweight	$12
Mar-21-19	Initiated	JP Morgan	Overweight	$14
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform	$37
Mar-14-18	Reiterated	Needham	Buy	$8 → $12

Show Previous Ratings

Jul-02-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jun-24-26 08:53AM	Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE) (InvestorsHub) -11.14%
Jun-18-26 07:45AM	cAMPfield lands $180M to build gut disease drug (BioPharma Dive)
Jun-15-26 08:00AM	Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients (GlobeNewswire)
Jun-05-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.15%
08:00AM	Loading…
Jun-03-26 08:00AM	Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA (GlobeNewswire) +6.30%
May-26-26 04:10PM	Spyre Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-05-26 08:08AM	Spyre Therapeutics: Q1 Earnings Snapshot (Associated Press)
08:00AM	Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-26 04:28PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.76%
Apr-16-26 04:15PM	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million (GlobeNewswire)
Apr-14-26 10:38PM	Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock (GlobeNewswire) +7.78%
Apr-13-26 04:46PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock (GlobeNewswire) +23.36%
01:12PM	Spyre stock soars as UC drug touts Entyvio-rivalling potential (Clinical Trials Arena)
09:53AM	Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results (Investor's Business Daily)
08:38AM	Loading…
08:38AM	Spyre drug for inflammatory bowel disease shows promise in early study (BioPharma Dive)
07:00AM	Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients (GlobeNewswire)
Apr-10-26 04:05PM	Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 (GlobeNewswire)
Apr-03-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Mar-16-26 08:00AM	Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 (GlobeNewswire) +10.48%
Mar-06-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Feb-24-26 04:05PM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-19-26 04:17PM	Spyre Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) +14.28%
04:02PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-18-26 08:00AM	Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach (GlobeNewswire)
Feb-16-26 12:23PM	Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 (Insider Monkey)
Feb-06-26 04:01PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) +6.62%
Jan-23-26 04:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire) -6.03%
Jan-15-26 11:35AM	Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating (Insider Monkey)
Jan-12-26 08:00AM	Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 (GlobeNewswire) +7.15%
04:05PM	Loading…
Jan-08-26 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Dec-08-25 11:30AM	A Short Squeeze Could Send This Little-Known Biotech Stock Soaring (Barchart)
Dec-05-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-17-25 12:15PM	Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 (Insider Monkey)
Nov-07-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Nov-04-25 04:54PM	Spyre Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
04:01PM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody (GlobeNewswire)
Oct-29-25 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 (GlobeNewswire)
Oct-15-25 04:15PM	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million (GlobeNewswire) +5.67%
Oct-13-25 09:07PM	Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock (GlobeNewswire) +11.02%
04:01PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (GlobeNewswire)
Oct-05-25 09:00AM	Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 (GlobeNewswire)
Oct-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Sep-24-25 08:35PM	Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial (Insider Monkey) +6.12% -8.18%
Sep-15-25 08:00AM	Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases (GlobeNewswire) -5.18%
Aug-05-25 04:17PM	Spyre Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -5.39%
04:02PM	Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-25 04:41PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jul-03-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire)
Jun-17-25 07:30AM	Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts (PR Newswire) -11.64%
Jun-16-25 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 (PR Newswire)
Jun-06-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
May-30-25 09:55AM	Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know (Zacks)
May-28-25 08:30AM	Spyre Therapeutics to Participate in Upcoming June Investor Conferences (PR Newswire)
May-13-25 09:55AM	How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% (Zacks)
May-08-25 04:05PM	Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) +9.64%
May-05-25 08:00AM	Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 (PR Newswire) -6.75%
May-02-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-04-25 04:05PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -8.58%
Mar-27-25 04:05PM	Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody (PR Newswire)
Mar-07-25 04:40PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Feb-27-25 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
Feb-25-25 08:00AM	Spyre Therapeutics to Participate in Upcoming March Investor Conferences (PR Newswire)
Feb-19-25 08:00AM	Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation (PR Newswire)
Feb-07-25 05:13PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.07%
Jan-13-25 08:00AM	Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts (PR Newswire)
Jan-03-25 05:20PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Dec-18-24 08:00AM	Spyre Therapeutics Added to the Nasdaq Biotechnology Index (PR Newswire) -8.31%
Dec-02-24 05:03PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
08:00AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies (PR Newswire)
Nov-25-24 05:11PM	Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-18-24 09:18PM	Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire) -6.17%
04:14PM	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants (PR Newswire)
Nov-12-24 07:30AM	Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing (PR Newswire) -8.97%
Nov-11-24 04:05PM	Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-47 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 (PR Newswire)
Nov-07-24 04:05PM	Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +5.00%
Nov-01-24 04:44PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Oct-30-24 04:05PM	Spyre Therapeutics to Participate in Upcoming November Investor Conferences (PR Newswire)
Oct-14-24 08:00AM	Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations (PR Newswire) +6.83%
Oct-04-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -5.66%
Oct-01-24 08:00AM	Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer (PR Newswire) -6.63%
Sep-10-24 04:47PM	Spyre Therapeutics to Participate in Upcoming Investor Conference (PR Newswire)
Aug-07-24 11:53PM	SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.72%
04:05PM	Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire) -5.22%
Jun-18-24 07:30AM	Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-47 Antibody, for the Treatment of Inflammatory Bowel Disease (PR Newswire)
Jun-03-24 05:23PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +5.26% -7.31%
May-29-24 08:30AM	Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference (PR Newswire)
May-15-24 07:30AM	Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors (PR Newswire)
May-09-24 10:54PM	SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +6.57%
04:02PM	Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-03-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
Apr-01-24 05:00PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) -7.27%
Mar-18-24 08:00AM	Spyre Therapeutics Announces $180 Million Private Placement (PR Newswire) -11.68%
Mar-04-24 08:50AM	Here's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strength (Zacks) +16.96%
Mar-01-24 05:25PM	Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire) +8.97%
Feb-29-24 04:05PM	Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +5.13%

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Ph.D.Dr. Cameron Turtle DPHIL

Chief Financial OfficerMr. Scott L. Burrows

L.L.M.Ms. Heidy Abreu King-Jones J.D.

M.D.Dr. Sheldon Sloan M.B.E.

Ph.D.Dr. Janet Gunzner-Toste M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burrows Scott L	Chief Financial Officer	Jul 01 '26	Option Exercise	14.50	7,500	108,750	105,494	Jul 02 09:33 PM
Burrows Scott L	Chief Financial Officer	Jul 01 '26	Sale	87.74	7,500	658,040	97,994	Jul 02 09:33 PM
Sloan Sheldon	Chief Medical Officer	Jul 01 '26	Option Exercise	27.46	8,334	228,852	8,334	Jul 02 09:33 PM
Sloan Sheldon	Chief Medical Officer	Jul 01 '26	Sale	87.70	8,334	730,896	0	Jul 02 09:33 PM
Turtle Cameron	Chief Executive Officer	Jul 01 '26	Sale	87.69	15,000	1,315,346	582,540	Jul 02 09:32 PM
CAMERON TURTLE	Director	Jul 01 '26	Proposed Sale	88.78	45,000	3,995,100		Jul 01 05:02 PM
Burrows Scott L	Chief Financial Officer	Jun 25 '26	Option Exercise	14.50	15,000	217,500	112,994	Jun 26 09:31 PM
Burrows Scott L	Chief Financial Officer	Jun 25 '26	Sale	87.13	15,000	1,307,000	97,994	Jun 26 09:31 PM
SCOTT BURROWS	Officer	Jun 25 '26	Proposed Sale	87.13	15,000	1,306,980		Jun 25 04:03 PM
Fairmount Healthcare Fund II L	Director	Jun 23 '26	Proposed Sale	85.31	4,684,781	399,658,667		Jun 23 09:57 PM
Fairmount Funds Management LLC	Director	Jun 23 '26	Sale	85.31	4,684,781	399,658,667	0	Jun 23 09:56 PM
HENDERSON MICHAEL THOMAS	Director	Jun 22 '26	Sale	100.00	20,000	2,000,000	68,606	Jun 23 09:32 PM
MICHAEL HENDERSON	Director	Jun 22 '26	Proposed Sale	88.34	20,000	1,766,800		Jun 22 04:44 PM
Sloan Sheldon	Chief Medical Officer	Jun 03 '26	Option Exercise	27.46	8,333	228,824	8,333	Jun 03 09:32 PM
Sloan Sheldon	Chief Medical Officer	Jun 03 '26	Sale	75.00	8,333	624,975	0	Jun 03 09:32 PM
Turtle Cameron	Chief Executive Officer	Jun 01 '26	Sale	70.43	15,000	1,056,486	597,540	Jun 03 09:31 PM
Burrows Scott L	Chief Financial Officer	Jun 01 '26	Option Exercise	14.50	7,500	108,750	105,494	Jun 03 09:30 PM
Burrows Scott L	Chief Financial Officer	Jun 01 '26	Sale	71.06	7,500	532,937	97,994	Jun 03 09:30 PM
SHELDON SLOAN	Officer	Jun 03 '26	Proposed Sale	69.16	16,667	1,152,690		Jun 03 04:27 PM
HENDERSON MICHAEL THOMAS	Director	May 08 '26	Sale	74.40	80,000	5,952,050	88,606	May 08 09:31 PM
MICHAEL HENDERSON	Director	May 08 '26	Proposed Sale	73.10	80,000	5,848,000		May 08 04:22 PM
Burrows Scott L	Chief Financial Officer	May 01 '26	Option Exercise	14.50	12,500	181,250	110,494	May 01 09:35 PM
Burrows Scott L	Chief Financial Officer	May 01 '26	Sale	71.37	12,500	892,125	97,994	May 01 09:35 PM
Sloan Sheldon	Chief Medical Officer	May 01 '26	Option Exercise	27.46	78,333	2,151,024	78,333	May 01 09:34 PM
Sloan Sheldon	Chief Medical Officer	May 01 '26	Sale	71.50	78,333	5,600,701	0	May 01 09:34 PM
Turtle Cameron	Chief Executive Officer	May 01 '26	Sale	71.37	15,000	1,070,507	612,540	May 01 09:34 PM
SHELDON SLOAN	Officer	May 01 '26	Proposed Sale	74.45	78,333	5,831,892		May 01 04:44 PM
SCOTT BURROWS	Officer	May 01 '26	Proposed Sale	74.45	27,500	2,047,375		May 01 04:44 PM
Turtle Cameron	Chief Executive Officer	Apr 01 '26	Sale	49.33	15,000	739,912	627,540	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Option Exercise	21.66	7,958	172,370	7,958	Apr 03 09:30 PM
Sloan Sheldon	Chief Medical Officer	Apr 01 '26	Sale	50.00	7,958	397,900	0	Apr 03 09:30 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Option Exercise	14.50	7,500	108,750	105,494	Apr 03 09:29 PM
Burrows Scott L	Chief Financial Officer	Apr 01 '26	Sale	49.34	7,500	370,076	97,994	Apr 03 09:29 PM
SHELDON SLOAN	Officer	Apr 01 '26	Proposed Sale	50.44	7,958	401,402		Apr 01 04:38 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Option Exercise	14.50	2,500	36,250	100,494	Mar 03 09:32 PM
Burrows Scott L	Chief Financial Officer	Mar 03 '26	Sale	40.65	2,500	101,620	97,994	Mar 03 09:32 PM
Turtle Cameron	Chief Executive Officer	Mar 02 '26	Sale	42.19	15,000	632,866	642,540	Mar 03 09:31 PM
SCOTT BURROWS	Officer	Mar 03 '26	Proposed Sale	42.49	10,000	424,900		Mar 03 04:43 PM
CAMERON TURTLE	Director	Mar 02 '26	Proposed Sale	43.01	60,000	2,580,600		Mar 02 04:31 PM
Turtle Cameron	Chief Executive Officer	Feb 02 '26	Sale	32.80	15,000	492,045	657,540	Feb 04 09:33 PM
Turtle Cameron	Chief Executive Officer	Jan 02 '26	Sale	30.68	15,000	460,134	671,907	Jan 06 09:36 PM
Turtle Cameron	Chief Executive Officer	Dec 01 '25	Sale	29.02	15,000	435,356	686,907	Dec 03 09:52 PM
Turtle Cameron	Chief Executive Officer	Nov 03 '25	Sale	23.33	45,000	1,049,778	701,907	Nov 05 09:15 PM
CAMERON TURTLE	Director	Nov 03 '25	Proposed Sale	24.46	90,000	2,201,400		Nov 03 04:24 PM
Burrows Scott L	Chief Financial Officer	Sep 02 '25	Sale	16.26	18,428	299,639	97,994	Sep 03 06:53 PM

VRDN Viridian Therapeutics Inc daily Stock Chart

Peers: KYMR RYTM BMRN KRYS NUVL VKTX AXSM MDGL INCY NBIX

| Held by: XBI VTI IWM VXF IWN SCHA VTWO DFAS IWC DFMC

Index	RUT
Market Cap	2.09B
Enterprise Value	1.51B
Income	-342.21M
Sales	70.92M
Book/sh	4.92
Cash/sh	6.90
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	252
IPO	Jun 18, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	29.43
P/B	3.84
P/C	2.74
P/FCF	-
EV/EBITDA	-
EV/Sales	21.27
Quick Ratio	15.15
Current Ratio	15.15
Debt/Eq	0.08
LT Debt/Eq	0.08
Option/Short	Yes / Yes

EPS (ttm)	-3.76
EPS next Y	-2.49
EPS next Q	-1.02
EPS this Y	-14.76%
EPS next Y	34.57%
EPS next 5Y	67.57%
EPS past 3/5Y	6.35% 36.07%
Sales past 3/5Y	241.95% 132.18%
EPS Y/Y TTM	7.01%
Sales Y/Y TTM	23382.78%
EPS Q/Q	3.94%
Sales Q/Q	95.83%
Earnings	May 05 BMO
EPS/Sales Surpr.	16.74% 290.58%

Insider Own	6.20%
Insider Trans	20.75%
Inst Own	103.72%
Inst Trans	8.28%
ROA	-47.20%
ROE	-55.17%
ROIC	-49.85%
Gross Margin	98.50%
Oper. Margin	-543.86%
Profit Margin	-482.55%
SMA20	3.47%
SMA50	9.40%
SMA200	-21.63%
Trades

Shs Outstand	110.43M
Shs Float	103.58M
Short Float	16.74%
Short Ratio	6.86
Short Interest	17.34M
52W High	34.29 -44.88%
52W Low	13.18 43.40%
Volatility	5.01% 4.68%
ATR (14)	0.88
RSI (14)	55.06
Beta	0.91
Rel Volume	0.01
Avg Volume	2.53M
Volume	1,577

Perf Week	-7.67%
Perf Month	17.10%
Perf Quarter	27.70%
Perf Half Y	-40.47%
Perf YTD	-39.27%
Perf Year	10.27%
Perf 3Y	-14.94%
Perf 5Y	5.70%
Perf 10Y	-81.74%
Recom	1.00
Target Price	36.12
Prev Close	18.99
Price	18.90
Change	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-29-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$31
Dec-10-25	Reiterated	Wedbush	Outperform	$42 → $47
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy	$44
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$37 → $27
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy	$30 → $38
Jun-11-24	Initiated	Wolfe Research	Outperform	$29
Jun-06-24	Initiated	Goldman	Buy	$23
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral	$25 → $20
Jun-14-23	Resumed	Credit Suisse	Outperform	$51
Jun-14-23	Initiated	BTIG Research	Buy	$46
May-30-23	Initiated	RBC Capital Mkts	Outperform	$44
Apr-17-23	Initiated	Wells Fargo	Overweight	$46
Mar-30-23	Initiated	Stifel	Buy	$49
Dec-19-22	Initiated	Needham	Buy	$45
Dec-19-22	Initiated	Cowen	Outperform	$45
Dec-16-22	Initiated	Credit Suisse	Outperform	$51

Show Previous Ratings

Jun-30-26 07:33AM	Viridian may have edge over Amgen in eye drug showdown, analysts argue (BioPharma Dive)
Jun-29-26 08:09AM	Comcast, Viridian Therapeutics jump premarket; Doximity slips (Investing.com)
Jun-26-26 06:57PM	VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval (Stocktwits)
06:00PM	Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease (Business Wire)
May-27-26 07:00AM	Viridian Therapeutics to Participate in Upcoming June Investor Conferences (Business Wire)
11:13PM	Loading…
May-06-26 11:13PM	Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million (Business Wire) -6.51%
08:13AM	Viridian Therapeutics stock up 35% after Phase III TED data release (Clinical Trials Arena)
May-05-26 04:05PM	Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock (Business Wire) +33.36%
10:24AM	PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results (InvestorsHub)
08:05AM	Can This Small Rival Take On Amgen's Eye Disease Blockbuster? (Investor's Business Daily)
08:04AM	Viridian data lift prospects for thyroid eye disease drug (BioPharma Dive)
07:01AM	Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress (Business Wire)
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease (Business Wire)
Apr-06-26 12:10PM	Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. (Barrons.com) -26.22%
09:03AM	Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug Disappoints (Investor's Business Daily)
06:48AM	Loading…
Mar-31-26 06:48AM	Viridian tumbles on positive data for key eye drug prospect (BioPharma Dive) +5.56%
Mar-30-26 12:32PM	Viridian Therapeutics shares fall over 30% after trial data disappoints (Proactive) -32.35%
11:37AM	Viridian Therapeutics stock sinks despite positive Phase III TED data (Clinical Trials Arena)
09:20AM	Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results (Investor's Business Daily)
07:01AM	Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL1 Clinical Trial in Active Thyroid Eye Disease (Business Wire)
Mar-06-26 10:20AM	RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating (Insider Monkey)
Feb-26-26 09:55AM	Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:01AM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-25-26 07:25PM	MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates (Zacks)
Jan-08-26 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-26 07:01AM	Viridian Therapeutics Prepares for Transformational 2026 (Business Wire)
Dec-22-25 07:00AM	Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease (Business Wire)
Dec-15-25 04:34PM	Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse (Investor's Business Daily)
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-05-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
10:14PM	Loading…
Nov-16-25 10:14PM	RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results (Insider Monkey)
Nov-07-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-05-25 08:20AM	Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.29%
07:01AM	Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 07:01AM	Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease (Business Wire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-28-25 03:21PM	Insiders Are Buying These 3 Stocks Hand Over Fist (24/7 Wall St.)
Oct-21-25 11:24PM	Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock (Business Wire) -8.83%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering (Business Wire)
06:55AM	Iambic partners with Jazz; Merck breaks ground on $3B plant (BioPharma Dive)
Oct-20-25 07:30AM	Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million (Business Wire)
Oct-02-25 04:00PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-15-25 07:01AM	Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates (Business Wire)
Sep-03-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-17-25 11:41PM	Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront (Insider Monkey)
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-31-25 05:37AM	Viridian and Kissei to advance veligrotug and VRDN-003 in Japan (Pharmaceutical Technology)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive) +6.02%
04:00AM	Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments (Business Wire)
Jul-15-25 08:58AM	Viridian Therapeutics' Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial (Insider Monkey) -5.13%
Jul-03-25 07:00AM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-25 07:00AM	Viridian Therapeutics to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 07:00AM	Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) (Business Wire) +7.80%
May-07-25 04:15PM	Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) (Business Wire)
May-06-25 08:10AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.31%
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results (Business Wire)
May-02-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-15-25 08:09AM	Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? (Zacks)
Apr-07-25 07:00AM	Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors (Business Wire)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
Mar-10-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-08-25 07:00AM	Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease (Business Wire) -8.42%
Dec-17-24 07:40AM	Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints (TipRanks)
Dec-16-24 04:09PM	Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen (Investor's Business Daily) +20.67%
09:28AM	Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease (Investor's Business Daily)
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease (Business Wire)
Dec-13-24 06:00PM	Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 (Business Wire)
Dec-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 07:00AM	Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data (Business Wire) -12.76%
Nov-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-24 11:25PM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (Business Wire) +5.60%
Sep-10-24 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire) +32.14%
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (Business Wire)
Sep-09-24 04:01PM	Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 (Business Wire)
Sep-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.23%
Aug-08-24 08:15AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-07-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 08:00AM	Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire)
Jul-08-24 10:38AM	3 Small-Cap Stocks With Explosive 2X Growth Potential (InvestorPlace)
Jul-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 09:48AM	Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-12-24 09:11AM	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug (Zacks) -5.94%
Jun-11-24 06:00AM	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease (Business Wire) +10.15%
Jun-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-31-24 08:00AM	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences (Business Wire)
May-10-24 08:00AM	Viridian Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
May-09-24 03:02AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com) -6.64%
May-08-24 11:54AM	VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:36AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements (GuruFocus.com)
08:25AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results (Business Wire)
May-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.62%

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves' disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

MBAMr. Stephen F. Mahoney J.D.

Chief Financial OfficerMr. Seth Harmon

MBAMr. Thomas W. Beetham J.D.

Chief Legal Officer & Corporate SecretaryMs. Jennifer Tousignant J.D.

M.P.H.Dr. Radhika Tripuraneni M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	May 11 '26	Buy	17.00	1,176,470	19,999,990	5,090,928	May 13 04:31 PM
Beetham Thomas W.	Officer	Mar 04 '26	Proposed Sale	30.19	3,048	92,004		Mar 04 04:29 PM
Tousignant Jennifer	Officer	Mar 04 '26	Proposed Sale	30.19	1,675	50,560		Mar 04 04:25 PM
Harmon Seth	Officer	Mar 04 '26	Proposed Sale	30.19	2,031	61,306		Mar 04 04:20 PM
Mahoney Stephen F.	Officer	Mar 04 '26	Proposed Sale	30.19	7,408	223,610		Mar 04 04:10 PM
Tousignant Jennifer	Chief Legal Officer	Dec 31 '25	Sale	31.16	2,272	70,796	0	Jan 02 05:25 PM
Tousignant Jennifer	Officer	Dec 31 '25	Proposed Sale	31.16	2,272	70,796		Dec 31 12:24 PM
Fairmount Funds Management LLC	Director	Oct 23 '25	Buy	22.00	454,545	9,999,990	3,914,458	Oct 27 04:30 PM

ZBIO Zenas Biopharma Inc daily Stock Chart

Peers: KYMR NUVL BMRN RYTM INCY KRYS VKTX AXSM MDGL NBIX

| Held by: XBI IWM VTI IWO IBB VXF SCHA IWC FFSM VTWO

Index	RUT
Market Cap	1.78B
Enterprise Value	1.41B
Income	-425.15M
Sales	0.00M
Book/sh	5.38
Cash/sh	11.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	167
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.23
P/C	2.48
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.94
Current Ratio	11.94
Debt/Eq	1.05
LT Debt/Eq	1.04
Option/Short	Yes / Yes

EPS (ttm)	-9.10
EPS next Y	-4.73
EPS next Q	-1.12
EPS this Y	43.01%
EPS next Y	1.67%
EPS next 5Y	21.09%
EPS past 3/5Y	-39.47% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-128.73%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-81.27%
Sales Q/Q	-100.00%
Earnings	May 13 BMO
EPS/Sales Surpr.	0.96% -

Insider Own	45.07%
Insider Trans	1.81%
Inst Own	63.62%
Inst Trans	24.19%
ROA	-78.63%
ROE	-137.11%
ROIC	-61.93%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	14.43%
SMA50	33.12%
SMA200	11.66%
Trades

Shs Outstand	62.38M
Shs Float	34.68M
Short Float	35.17%
Short Ratio	16.78
Short Interest	12.20M
52W High	44.60 -36.91%
52W Low	11.10 153.51%
Volatility	6.98% 7.81%
ATR (14)	1.61
RSI (14)	66.25
Beta	-0.94
Rel Volume	0.01
Avg Volume	726.93K
Volume	241

Perf Week	1.66%
Perf Month	58.45%
Perf Quarter	33.75%
Perf Half Y	75.00%
Perf YTD	-22.50%
Perf Year	119.50%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.25
Target Price	42.12
Prev Close	27.88
Price	28.14
Change	0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Jun-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.46%
Jun-11-26 04:15PM	Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire) +11.49%
Jun-02-26 07:05PM	Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine (GlobeNewswire) -5.72%
May-28-26 07:05AM	Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD (GlobeNewswire)
May-19-26 07:05AM	Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress (GlobeNewswire) +5.50%
04:15PM	Loading…
May-18-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.80%
May-13-26 06:50AM	Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor (GlobeNewswire)
06:00AM	Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 12:12AM	Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million (GlobeNewswire) -17.82%
Mar-26-26 04:01PM	Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock (GlobeNewswire)
Mar-16-26 06:01PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-26 10:56AM	Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory (Insider Monkey)
Feb-20-26 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:09AM	Loading…
Feb-19-26 07:09AM	Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 (Insider Monkey)
Feb-16-26 04:07AM	Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit (MarketBeat)
Feb-09-26 07:05AM	Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 (GlobeNewswire)
Feb-04-26 07:05AM	Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-26 09:01AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Jan-07-26 06:46AM	Zenas BioPharma Touts Phase 3 Win, But Stock Crashes (Benzinga) +8.62%
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks) -8.49%
06:25AM	Zenas stock drops 51% despite lead assets Phase III rare disease win (Clinical Trials Arena)
Jan-05-26 04:23PM	Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. (Investor's Business Daily) -51.86%
07:05AM	Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
06:26AM	Zenas shares crash after top drug misses expectations in immune disease study (BioPharma Dive)
Dec-19-25 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +17.10%
Dec-15-25 07:05AM	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus (GlobeNewswire) -19.71%
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
07:25AM	Loading…
Dec-03-25 07:25AM	Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation (Insider Monkey) +6.29%
Nov-12-25 07:05AM	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) +8.41%
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat) -5.06%
08:35AM	Zenas bifunctional mAb scores at Phase II in relapsing MS (Clinical Trials Arena)
06:00AM	Incyte trims pipeline; Zenas surges on MS drug results (BioPharma Dive)
Oct-27-25 07:05AM	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis (GlobeNewswire) +33.08%
Oct-08-25 05:00AM	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) +24.22%
Sep-02-25 07:05AM	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire) +9.50%
Aug-26-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-12-25 07:05AM	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.68%
Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

M.B.A.Mr. Leon Oliver Moulder Jr.

COO & PresidentMr. Joseph L. Farmer

Head of Research & Development and Chief Medical OfficerDr. Lisa von Moltke M.D.

Chief Business Officer & CFOMs. Jennifer A. Fox

Chief Technical OfficerDr. Heinrich Schlieker Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	May 18 '26	Buy	16.88	60,000	1,012,800	96,928	May 18 09:12 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 29 '26	Buy	17.62	35,000	616,700	1,786,039	Apr 29 07:21 PM
MOULDER LEON O JR	Chief Executive Officer	Apr 28 '26	Buy	18.02	25,000	450,500	1,751,039	Apr 29 07:21 PM
Lu Hongbo	Director	Mar 31 '26	Buy	18.63	3,768	70,198	426,736	Apr 02 05:02 PM
Fairmount Funds Management LLC	Director	Mar 31 '26	Buy	20.00	150,000	3,000,000	2,359,025	Apr 01 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 31 '26	Buy	19.31	34,000	656,540	1,726,039	Mar 31 08:14 PM
MOULDER LEON O JR	Chief Executive Officer	Mar 30 '26	Buy	18.23	20,000	364,600	1,692,039	Mar 31 08:14 PM
Lu Hongbo	Director	Mar 31 '26	Buy	20.00	75,000	1,500,000	422,968	Mar 31 05:00 PM
Lu Hongbo	Director	Feb 11 '26	Buy	22.50	25,985	584,662	347,968	Feb 13 05:35 PM
Allen Patricia L	Director	Feb 12 '26	Buy	24.85	15,700	390,088	15,700	Feb 13 05:06 PM
Allen Patricia L	Director	Feb 13 '26	Buy	26.36	4,160	109,658	19,860	Feb 13 05:06 PM
MOULDER LEON O JR	Chief Executive Officer	Feb 02 '26	Buy	17.96	57,000	1,023,720	423,155	Feb 03 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 07 '26	Buy	16.38	50,000	819,000	316,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 08 '26	Buy	16.30	30,000	489,000	346,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 09 '26	Buy	16.55	20,000	331,000	366,155	Jan 09 09:42 PM
Nunn Jason Raleigh	Director	Oct 09 '25	Buy	19.00	63,158	1,200,002	1,173,395	Oct 14 05:16 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Oct 09 '25	Buy	19.00	126,315	2,399,985	1,917,895	Oct 14 05:14 PM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	19.00	105,265	2,000,035	1,832,669	Oct 14 08:59 AM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	20.85	11,990	249,992	11,990	Oct 14 08:59 AM
MOULDER LEON O JR	See Remarks	Oct 07 '25	Buy	20.85	36,928	769,949	36,928	Oct 09 05:24 PM
Fairmount Funds Management LLC	Director	Oct 07 '25	Buy	19.00	316,219	6,008,161	2,209,025	Oct 09 04:15 PM
Lu Hongbo	Director	Oct 07 '25	Buy	19.00	263,160	5,000,040	321,983	Oct 09 03:37 PM

COGT Cogent Biosciences Inc daily Stock Chart

Peers: KYMR BMRN RYTM APGE KRYS NUVL VKTX AXSM MDGL NBIX

| Held by: VTI IWM VB XBI VBR VXF IWO IBB SCHA VTWO

Index	RUT
Market Cap	6.49B
Enterprise Value	5.93B
Income	-354.30M
Sales	0.00M
Book/sh	3.18
Cash/sh	5.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	258
IPO	Mar 29, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	11.95
P/C	7.49
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.14
Current Ratio	15.14
Debt/Eq	0.39
LT Debt/Eq	0.39
Option/Short	Yes / Yes

EPS (ttm)	-2.52
EPS next Y	-0.78
EPS next Q	-0.55
EPS this Y	-3.94%
EPS next Y	65.17%
EPS next 5Y	-
EPS past 3/5Y	-2.22% 30.89%
Sales past 3/5Y	- -
EPS Y/Y TTM	0.01%
Sales Y/Y TTM	-
EPS Q/Q	5.50%
Sales Q/Q	-
Earnings	May 05 BMO
EPS/Sales Surpr.	0.49% -

Insider Own	13.10%
Insider Trans	-31.93%
Inst Own	98.06%
Inst Trans	7.92%
ROA	-59.71%
ROE	-85.72%
ROIC	-41.93%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.43%
SMA50	8.04%
SMA200	14.63%
Trades

Shs Outstand	170.77M
Shs Float	148.52M
Short Float	11.01%
Short Ratio	6.79
Short Interest	16.35M
52W High	43.73 -13.13%
52W Low	10.38 265.99%
Volatility	4.08% 4.24%
ATR (14)	1.55
RSI (14)	55.54
Beta	0.38
Rel Volume	0.00
Avg Volume	2.41M
Volume	146

Perf Week	-5.05%
Perf Month	16.46%
Perf Quarter	4.03%
Perf Half Y	7.47%
Perf YTD	6.95%
Perf Year	242.56%
Perf 3Y	203.19%
Perf 5Y	465.33%
Perf 10Y	-
Recom	1.31
Target Price	54.25
Prev Close	37.46
Price	37.99
Change	1.41%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-16-26	Resumed	Jefferies	Buy
Nov-10-25	Upgrade	Wedbush	Neutral → Outperform	$38
Nov-10-25	Upgrade	Stifel	Hold → Buy	$40
Oct-16-25	Initiated	Stifel	Hold	$16
Sep-03-25	Initiated	Raymond James	Strong Buy	$30
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$17
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral	$14 → $8
Feb-08-24	Initiated	Citigroup	Buy	$11
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral	$5
Dec-08-23	Initiated	JP Morgan	Overweight	$18
Apr-28-23	Initiated	Robert W. Baird	Outperform	$20
Mar-27-23	Resumed	H.C. Wainwright	Buy	$28
Dec-14-22	Initiated	Needham	Buy	$24
Jun-28-22	Initiated	Guggenheim	Buy	$15
Oct-11-21	Initiated	H.C. Wainwright	Buy	$25
Jun-09-21	Resumed	Jefferies	Buy	$20
Dec-23-20	Initiated	Piper Sandler	Overweight	$22
Oct-14-20	Initiated	Ladenburg Thalmann	Buy	$4

Show Previous Ratings

Jun-30-26 08:00AM	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Jun-12-26 08:01AM	Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress (GlobeNewswire)
08:00AM	Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress (GlobeNewswire)
May-30-26 08:00AM	Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-28-26 08:00AM	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST (GlobeNewswire)
08:00AM	Loading…
May-27-26 08:00AM	Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 09:30AM	Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress (GlobeNewswire)
May-05-26 08:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results (GlobeNewswire)
Apr-21-26 08:00AM	Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-17-26 08:00AM	Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
Apr-10-26 05:28PM	Southwest Airlines, Colliers International, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-01-26 08:00AM	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire) -8.44%
Mar-30-26 03:59PM	Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts (Proactive)
Mar-16-26 08:00AM	Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire)
Mar-02-26 02:57AM	Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval (Insider Monkey)
09:45AM	Loading…
Feb-28-26 09:45AM	Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-27-26 04:06PM	Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval (Insider Monkey)
Feb-17-26 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-10-26 08:00AM	Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting (GlobeNewswire)
Feb-02-26 04:17AM	Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) (Insider Monkey) +5.71%
Jan-30-26 07:39PM	Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors (Barrons.com)
Jan-27-26 08:06AM	Cogent Biosciences announcse U.S. BTD for bezuclastinib (TipRanks)
Jan-26-26 10:06AM	Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag (Benzinga)
08:00AM	Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
Jan-20-26 08:00AM	Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) (GlobeNewswire)
Jan-12-26 08:00AM	Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio (GlobeNewswire)
Jan-11-26 01:05AM	H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) (Insider Monkey)
Jan-06-26 08:00AM	Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 11:37AM	Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. (Barrons.com)
Dec-30-25 08:00AM	Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis (GlobeNewswire)
10:05AM	Loading…
Dec-28-25 10:05AM	JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update (Insider Monkey)
Dec-11-25 08:24PM	Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank (Zacks) +5.17%
Dec-08-25 07:30AM	Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Dec-06-25 09:30AM	Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) (GlobeNewswire)
Nov-23-25 07:02AM	Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So (Insider Monkey)
Nov-20-25 11:38AM	COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know (Zacks)
Nov-16-25 11:16AM	Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress (Insider Monkey)
Nov-14-25 08:00AM	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire)
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive) +5.51%
Nov-11-25 11:16PM	Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 (GlobeNewswire)
12:49PM	Cogent Biosciences (COGT) Climbs to New Record High on Cancer Treatment Drug Trial (Insider Monkey)
Nov-10-25 04:01PM	Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock (GlobeNewswire) +119.03%
01:48PM	Cogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug. (Barrons.com)
10:45AM	Cogent Biosciences Stock Surges 127%. Why Investors See Promise in Its Cancer Drug. (Barrons.com)
10:43AM	Cogent Biosciences Hits 7-Year High, Up 120% On Its New Stomach Cancer Promise (Investor's Business Daily)
07:00AM	Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
06:14AM	Stock Market Today: Nasdaq, S&P 500, Russell Jump Over 1% As Tech Rebound, Government Reopening Infuses Optimism into Markets (TheStreet)
Nov-03-25 09:01AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results (GlobeNewswire)
09:00AM	Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire)
Oct-24-25 12:30PM	Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-20-25 08:32AM	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib (GlobeNewswire)
Sep-29-25 04:05PM	Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 12:59PM	Cogent, Dime added to Raymond James analyst favorites list (Investing.com)
Aug-26-25 08:00AM	Cogent Biosciences Announces Participation in the Citi Biopharma Conference (GlobeNewswire)
Aug-05-25 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results (GlobeNewswire) -5.73%
Jul-31-25 05:31PM	KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 \| DelveInsight (PR Newswire)
Jul-24-25 11:47PM	Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline (Insider Monkey)
Jul-18-25 06:19PM	Rocket, TaskUS, Appian, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-16-25 12:23PM	Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating (Insider Monkey)
Jul-10-25 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-08-25 09:36PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire) +6.34%
04:26PM	Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock (GlobeNewswire)
10:54AM	COGT Stock Soars on Phase III Systemic Mastocytosis Study Success (Zacks)
Jul-07-25 07:06AM	Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis (GlobeNewswire) +23.35%
Jun-11-25 08:00AM	Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing (GlobeNewswire)
May-29-25 08:00AM	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) +12.91%
May-13-25 09:55AM	Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade (Zacks)
08:50AM	Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
May-06-25 08:00AM	Cogent Biosciences Reports First Quarter 2025 Financial Results (GlobeNewswire) -15.62%
May-05-25 07:57AM	Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey) -5.11%
Apr-25-25 08:08AM	Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders (GlobeNewswire)
Apr-20-25 06:16AM	Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts (Insider Monkey)
Apr-16-25 10:03AM	Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -12.32%
Apr-09-25 04:28PM	Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement (Seeking Alpha) +7.73% -9.87%
Mar-25-25 04:31PM	Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -6.76% -6.23%
Mar-20-25 08:32AM	Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? (Zacks)
Mar-07-25 08:00AM	Cogent Biosciences Announces Participation in the Leerink Healthcare Conference (GlobeNewswire) -5.40%
Feb-27-25 08:00AM	Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire)
Feb-25-25 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.30%
Feb-10-25 09:15AM	Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting (GlobeNewswire)
Jan-30-25 08:00AM	Cogent Biosciences to Participate in the Guggenheim Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire)
Jan-08-25 08:00AM	Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire) +8.77%
Dec-08-24 12:00PM	Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Nov-05-24 09:00AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire) -15.84%
Oct-23-24 07:00AM	Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 08:03AM	Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target (Insider Monkey)
Sep-03-24 08:00AM	Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis (GlobeNewswire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-06-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-28-24 09:18AM	Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting (Zacks)
Jun-27-24 08:00AM	Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial (GlobeNewswire)
Jun-14-24 07:30AM	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire) -6.18%
May-23-24 05:05PM	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer (GlobeNewswire) -6.72% +9.75%
05:01PM	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting (GlobeNewswire)
May-07-24 01:52PM	COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Cogent Biosciences Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-09-24 09:00AM	Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor (GlobeNewswire) +7.21%
Mar-13-24 07:06AM	5 Best Biotech Stocks To Buy Under $20 (Insider Monkey)

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

PresidentMr. Andrew R. Robbins M.B.A.

CPAMr. John L. Green C.A.

Chief Scientific OfficerDr. John Edward Robinson Ph.D.

Chief Medical OfficerDr. Jessica Sachs M.D.

Chief Commercial OfficerMr. Cole Pinnow

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Healthcare Fund II L	Director	Mar 31 '26	Proposed Sale	34.66	7,000,000	242,620,000		Mar 31 09:30 PM
Fairmount Funds Management LLC	Director	Mar 31 '26	Sale	34.66	7,000,000	242,620,000	5,503,418	Mar 31 09:30 PM
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	36.40	3,500,000	127,400,000	5,503,418	Jan 22 08:09 PM
Fairmount Healthcare Fund II L	Director	Jan 22 '26	Proposed Sale	36.40	3,500,000	127,400,000		Jan 22 08:05 PM
Kearns Evan	Chief Legal Officer	Dec 26 '25	Sale	38.70	65,000	2,515,500	109,398	Dec 30 04:01 PM
Green John L.	Chief Financial Officer	Dec 26 '25	Sale	38.68	77,000	2,978,360	131,834	Dec 30 04:01 PM
Sachs Jessica	Chief Medical Officer	Dec 26 '25	Sale	38.70	82,642	3,198,245	133,938	Dec 30 04:01 PM
Robinson John Edward	Chief Scientific Officer	Dec 26 '25	Sale	38.74	90,000	3,486,600	140,002	Dec 30 04:01 PM
JESSICA SACHS	Officer	Dec 26 '25	Proposed Sale	38.70	82,642	3,198,435		Dec 29 09:27 AM
JOHN ROBINSON	Officer	Dec 26 '25	Proposed Sale	38.74	90,000	3,486,276		Dec 29 09:08 AM
JOHN GREEN	Officer	Dec 26 '25	Proposed Sale	38.68	77,000	2,978,322		Dec 29 09:06 AM
EVAN D KEARNS	Officer	Dec 26 '25	Proposed Sale	38.70	65,000	2,515,175		Dec 29 09:05 AM

APGE Apogee Therapeutics Inc daily Stock Chart

Peers: KYMR BMRN MDGL RYTM VKTX KRYS NUVL AXSM INCY NBIX

| Held by: XBI IWM VTI IWO IBB VXF SCHA VTWO ITOT VHT

Index	RUT
Market Cap	10.07B
Enterprise Value	9.02B
Income	-274.62M
Sales	0.00M
Book/sh	16.77
Cash/sh	14.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	261
IPO	Jul 14, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.98
P/C	9.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	32.59
Current Ratio	32.59
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.33
EPS next Y	-5.54
EPS next Q	-1.07
EPS this Y	-5.26%
EPS next Y	-24.72%
EPS next 5Y	-12.96%
EPS past 3/5Y	-75.11% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-22.17%
Sales Y/Y TTM	-
EPS Q/Q	-11.87%
Sales Q/Q	-
Earnings	May 11 BMO
EPS/Sales Surpr.	0.83% -

Insider Own	24.30%
Insider Trans	-10.05%
Inst Own	75.53%
Inst Trans	-19.25%
ROA	-27.35%
ROE	-28.47%
ROIC	-21.78%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	7.99%
SMA50	34.86%
SMA200	73.86%
Trades

Shs Outstand	61.40M
Shs Float	56.91M
Short Float	9.07%
Short Ratio	2.04
Short Interest	5.16M
52W High	133.88 0.01%
52W Low	34.34 289.92%
Volatility	0.34% 1.73%
ATR (14)	2.73
RSI (14)	81.35
Beta	0.34
Rel Volume	0.00
Avg Volume	2.53M
Volume	63

Perf Week	0.27%
Perf Month	49.61%
Perf Quarter	54.37%
Perf Half Y	71.69%
Perf YTD	77.40%
Perf Year	244.39%
Perf 3Y	530.71%
Perf 5Y	-
Perf 10Y	-
Recom	2.60
Target Price	132.79
Prev Close	133.82
Price	133.90
Change	0.06%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Initiated	Rothschild & Co Redburn	Buy	$140
Mar-18-26	Initiated	Truist	Hold	$83
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$83
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight	$95
Dec-10-25	Initiated	Deutsche Bank	Buy	$103
Nov-03-25	Initiated	Craig Hallum	Buy	$109
Oct-21-25	Initiated	Mizuho	Outperform	$105
Sep-25-25	Initiated	RBC Capital Mkts	Outperform	$60
Jul-07-25	Reiterated	BTIG Research	Buy	$100 → $115
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Show Previous Ratings

Jul-06-26 08:02PM	Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-02-26 03:38PM	Are APGE, INVE, CBAN, FSRL Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-26-26 02:39PM	Healthcare stocks have become a haven for investors ditching tech (MarketWatch)
Jun-25-26 01:53PM	Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-22-26 11:04PM	Why Did INTC, KEEL, APGE Stocks Hit 52-Week Highs Today? (Stocktwits) +46.66%
04:20PM	Loading…
04:20PM	Are ACA, CZR, APGE Obtaining Fair Deals for their Shareholders? (PR Newswire)
04:08PM	AbbVie Goes On The Offensive With $10.9 Billion Takeover (Investor's Business Daily)
02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
11:33AM	AbbVie deepens immunology legacy in $10.9bn Apogee buyout (Pharmaceutical Technology)
11:12AM	AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug \| Stock Movers (Bloomberg)
10:04AM	AbbVie to acquire Apogee Therapeutics in $10.9B deal (Proactive)
09:08AM	Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal (Investing.com)
09:08AM	Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics (Barrons.com)
08:58AM	AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV) (InvestorsHub)
08:32AM	AbbVie acquires Apogee Therapeutics for $10.9 billion (Quartz)
07:42AM	Loading…
07:42AM	AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash (The Wall Street Journal)
07:06AM	Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion. (Barrons.com)
07:00AM	AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio (PR Newswire)
Jun-20-26 12:11PM	AbbVie would gain an experimental eczema drug by buying biotech: report (MarketWatch)
Jun-19-26 04:09PM	Stocks Stall as Iran Nuclear Talks Hit Early Snag: Markets Wrap (Bloomberg)
May-28-26 04:01PM	Apogee Therapeutics to Participate in Upcoming June Conferences (GlobeNewswire) +5.55%
02:43PM	Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program (Proactive)
May-27-26 04:06PM	Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results (Investor's Business Daily) -6.11%
02:33PM	Blackstone Backs Apogee With Up To $1.3 Billion (GuruFocus.com)
08:06AM	Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG) (InvestorsHub)
06:31AM	Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart (GlobeNewswire)
06:30AM	Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
May-26-26 04:01PM	Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026 (GlobeNewswire)
May-11-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Mar-26-26 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million (GlobeNewswire)
09:53PM	Loading…
Mar-24-26 09:53PM	Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering (GlobeNewswire) -7.87% +7.58%
Mar-23-26 04:01PM	Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering (GlobeNewswire) +19.99%
10:01AM	How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug (Investor's Business Daily)
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:30AM	Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Mar-22-26 07:51PM	Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 (GlobeNewswire)
Mar-18-26 09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-10-26 08:04AM	Wedbush Raises Price Target on Apogee Therapeutics (APGE) (Insider Monkey)
Mar-04-26 06:34AM	Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference (MarketBeat) +5.56%
Mar-02-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 07:30AM	Apogee Therapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-18-26 07:39PM	End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations (Insider Monkey)
Feb-16-26 12:23PM	Here is Why Apogee Therapeutics (APGE) Appears Attractive (Insider Monkey)
Feb-12-26 09:07PM	Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference (MarketBeat) +5.32%
Feb-05-26 08:00AM	Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-30-26 07:39PM	Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors (Barrons.com) -6.39%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
Jan-06-26 06:00AM	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook (GlobeNewswire)
Jan-05-26 04:01PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 (GlobeNewswire)
Dec-09-25 12:19AM	Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth (Insider Monkey)
Nov-11-25 09:40AM	Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? (Zacks) +10.89%
Nov-10-25 07:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody (GlobeNewswire)
Nov-03-25 07:30AM	Apogee Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Oct-30-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade (Zacks)
Oct-17-25 09:55PM	BTIG Maintains a Buy on Apogee Therapeutics (APGE) (Insider Monkey)
Oct-14-25 09:55AM	Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? (Zacks)
Oct-10-25 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million (GlobeNewswire)
Oct-09-25 05:26PM	Why Apogee Therapeutics Stock Triumphed on Thursday (Motley Fool) +12.64%
01:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
Oct-08-25 09:52PM	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +18.90%
04:01PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-30-25 04:00AM	RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating (Insider Monkey)
Sep-15-25 09:09AM	BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis (Insider Monkey)
Sep-11-25 07:30AM	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress (GlobeNewswire)
Sep-03-25 07:30AM	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-11-25 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:55AM	Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks) -5.24%
Jul-31-25 11:38AM	Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug (Insider Monkey)
Jul-16-25 09:38AM	BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating (Insider Monkey)
Jul-14-25 07:52AM	Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) (Insider Monkey)
Jul-08-25 03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com) -7.21%
02:26PM	Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors (Insider Monkey)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily) -17.32%
10:09AM	Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot (Investor's Business Daily)
06:00AM	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jul-06-25 06:00PM	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 (GlobeNewswire)
04:01AM	Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma (Insider Monkey)
Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)

Apogee Therapeutics, Inc. is a clinical stage biotechnology company. It offers treatment of atopic dermatitis (AD), ashma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded by Andrew Gottesdiener and Nimish P. Shah in 2022 and is headquartered in Waltham, MA.

CEO & DirectorDr. Michael Thomas Henderson M.D.

Chief Financial OfficerMs. Jane Pritchett V. Henderson

Chief Medical OfficerDr. Carl Linden Dambkowski M.D.

Vice President of Investor RelationsMs. Noel Kurdi

Chief Legal Officer & Corporate SecretaryMr. Matthew Batters J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jul 08 '26	Sale	133.63	20,000	2,672,600	995,987	Jul 10 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 01 '26	Option Exercise	22.86	4,125	94,298	183,373	Jul 02 08:13 PM
Dambkowski Carl	Chief Medical Officer	Jul 01 '26	Sale	132.74	5,500	730,070	177,873	Jul 02 08:13 PM
CARL DAMBKOWSKI	Officer	Jul 01 '26	Proposed Sale	132.73	16,500	2,190,045		Jul 01 05:00 PM
Dambkowski Carl	Chief Medical Officer	Jun 22 '26	Sale	132.60	26,400	3,500,640	179,248	Jun 24 08:01 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jun 22 '26	Sale	132.54	80,000	10,603,200	1,015,987	Jun 24 08:00 PM
CARL DAMBKOWSKI	Officer	Jun 22 '26	Proposed Sale	90.38	15,400	1,391,852		Jun 22 04:48 PM
HENDERSON MICHAEL THOMAS	Officer	Jun 22 '26	Proposed Sale	132.54	80,000	10,603,532		Jun 22 10:40 AM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jun 10 '26	Sale	83.38	20,000	1,667,622	1,095,987	Jun 12 05:05 PM
Dambkowski Carl	Chief Medical Officer	Jun 03 '26	Option Exercise	22.86	4,125	94,298	211,148	Jun 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jun 03 '26	Sale	78.71	5,500	432,905	205,648	Jun 05 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	May 13 '26	Sale	82.09	20,000	1,641,711	1,115,987	May 15 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	May 13 '26	Proposed Sale	82.47	60,000	4,948,200		May 13 10:34 AM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Option Exercise	22.86	4,125	94,298	212,523	May 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Sale	84.14	5,500	462,784	207,023	May 08 08:00 PM
CARL DAMBKOWSKI	Officer	May 06 '26	Proposed Sale	83.29	22,000	1,832,380		May 06 04:25 PM
Henderson Jane	Chief Financial Officer	May 01 '26	Sale	82.04	2,000	164,080	173,371	May 04 08:00 PM
JANE HENDERSON	Officer	May 01 '26	Proposed Sale	82.89	2,000	165,780		May 01 04:45 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 16 '26	Option Exercise	22.86	3,000	68,580	1,135,987	Apr 20 04:05 PM
Henderson Jane	Chief Financial Officer	Apr 16 '26	Sale	90.00	2,000	180,000	175,371	Apr 17 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 08 '26	Sale	82.58	20,000	1,651,664	1,132,987	Apr 10 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Option Exercise	22.86	4,125	94,298	213,898	Apr 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Sale	84.84	5,500	466,619	208,398	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Apr 01 '26	Sale	85.01	2,000	170,020	177,371	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 25 '26	Sale	85.00	2,000	170,000	179,371	Mar 27 08:00 PM
JANE HENDERSON	Officer	Mar 25 '26	Proposed Sale	73.00	6,000	438,000		Mar 25 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 11 '26	Sale	74.78	20,000	1,495,605	1,152,987	Mar 13 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Option Exercise	22.86	4,125	94,298	215,273	Mar 06 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Sale	71.06	5,500	390,825	209,773	Mar 06 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 02 '26	Sale	70.22	2,000	140,431	181,371	Mar 04 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 11 '26	Sale	63.35	20,000	1,266,953	1,172,987	Feb 13 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Feb 11 '26	Proposed Sale	64.00	60,000	3,840,000		Feb 11 10:42 AM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Option Exercise	22.86	4,125	94,298	216,648	Feb 04 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Sale	65.79	5,500	361,860	211,148	Feb 04 08:02 PM
Henderson Jane	Chief Financial Officer	Feb 02 '26	Sale	65.81	2,000	131,630	183,371	Feb 04 08:01 PM
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	76.30	1,750,000	133,525,000	298,647	Jan 22 08:07 PM
Fairmount Healthcare Fund II L	Director	Jan 22 '26	Proposed Sale	76.30	1,750,000	133,525,000		Jan 22 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 14 '26	Sale	81.11	20,000	1,622,159	1,192,987	Jan 16 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Option Exercise	22.86	14,025	320,612	231,223	Jan 09 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Sale	77.84	18,700	1,455,613	212,523	Jan 09 08:00 PM
CARL DAMBKOWSKI	Officer	Jan 07 '26	Proposed Sale	78.25	35,200	2,754,400		Jan 07 04:27 PM
Henderson Jane	Chief Financial Officer	Jan 02 '26	Sale	74.86	6,000	449,146	187,371	Jan 06 08:00 PM
Henderson Jane	Chief Financial Officer	Jan 06 '26	Sale	80.00	2,000	160,000	185,371	Jan 06 08:00 PM
JANE HENDERSON	Officer	Jan 02 '26	Proposed Sale	75.48	12,000	905,760		Jan 02 04:31 PM
Henderson Jane	Chief Financial Officer	Dec 19 '25	Sale	80.00	1,500	120,000	193,371	Dec 23 08:00 PM
JANE HENDERSON	Officer	Dec 19 '25	Proposed Sale	77.35	1,500	116,025		Dec 19 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 10 '25	Sale	75.38	20,000	1,507,657	1,212,987	Dec 12 08:00 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '25	Sale	75.00	10,900	817,500	271,108	Dec 05 08:03 PM
Henderson Jane	Chief Financial Officer	Dec 04 '25	Sale	75.00	1,500	112,500	194,871	Dec 05 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '25	Sale	75.01	40,000	3,000,400	1,232,987	Dec 05 08:00 PM
JANE HENDERSON	Officer	Dec 04 '25	Proposed Sale	74.55	1,500	111,825		Dec 04 04:43 PM
CARL DAMBKOWSKI	Officer	Dec 04 '25	Proposed Sale	74.55	10,900	812,595		Dec 04 04:41 PM
Henderson Jane	Chief Financial Officer	Nov 25 '25	Sale	70.00	1,500	105,000	196,371	Nov 28 08:00 PM
JANE HENDERSON	Officer	Nov 25 '25	Proposed Sale	67.85	1,500	101,775		Nov 25 04:28 PM
Henderson Jane	Chief Financial Officer	Nov 14 '25	Sale	65.00	2,000	130,000	197,871	Nov 14 08:00 PM
JANE HENDERSON	Officer	Nov 14 '25	Proposed Sale	62.97	2,000	125,940		Nov 14 04:31 PM
Henderson Jane	Chief Financial Officer	Nov 11 '25	Sale	60.00	1,000	60,000	199,871	Nov 13 08:37 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 13 '25	Sale	63.01	20,000	1,260,236	1,272,987	Nov 13 08:24 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 13 '25	Proposed Sale	66.98	100,000	6,697,800		Nov 13 10:33 AM
JANE HENDERSON	Officer	Nov 11 '25	Proposed Sale	56.77	1,000	56,770		Nov 12 07:03 AM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Option Exercise	22.86	8,060	184,252	292,793	Nov 07 08:00 PM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Sale	55.07	10,785	593,903	282,008	Nov 07 08:00 PM
CARL DAMBKOWSKI	Officer	Nov 05 '25	Proposed Sale	53.90	10,785	581,312		Nov 05 04:17 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Option Exercise	22.86	2,385	54,521	289,843	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Sale	39.80	5,110	203,378	284,733	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Sep 03 '25	Sale	37.87	2,725	103,198	233,548	Sep 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Aug 06 '25	Sale	37.78	2,725	102,950	236,273	Aug 08 08:00 PM

CBIO Crescent Biopharma Inc daily Stock Chart

Peers: INCY BMRN VKTX KRYS KYMR NUVL RYTM AXSM MDGL NBIX

| Held by: VTI IWM IWO VXF IWC VHT AVSC VFMO BBC RSSL

Index	RUT
Market Cap	432.60M
Enterprise Value	248.98M
Income	-162.08M
Sales	11.88M
Book/sh	6.52
Cash/sh	6.86
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	44
IPO	Jan 10, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	36.41
P/B	2.41
P/C	2.29
P/FCF	-
EV/EBITDA	-
EV/Sales	20.96
Quick Ratio	13.78
Current Ratio	13.78
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-12.48
EPS next Y	-3.25
EPS next Q	-0.78
EPS this Y	75.02%
EPS next Y	-1.49%
EPS next 5Y	35.34%
EPS past 3/5Y	45.01% 33.26%
Sales past 3/5Y	424.86% 1.31%
EPS Y/Y TTM	72.70%
Sales Y/Y TTM	-100.00%
EPS Q/Q	78.91%
Sales Q/Q	-
Earnings	Apr 29 AMC
EPS/Sales Surpr.	20.33% 180.03%

Insider Own	22.66%
Insider Trans	-1.08%
Inst Own	79.13%
Inst Trans	8.18%
ROA	-158.03%
ROE	-173.14%
ROIC	-87.64%
Gross Margin	98.75%
Oper. Margin	-1372.85%
Profit Margin	-1363.94%
SMA20	-10.01%
SMA50	-14.75%
SMA200	7.37%
Trades

Shs Outstand	27.57M
Shs Float	21.32M
Short Float	17.23%
Short Ratio	11.54
Short Interest	3.67M
52W High	27.41 -42.76%
52W Low	8.72 79.93%
Volatility	6.92% 7.44%
ATR (14)	1.38
RSI (14)	36.33
Beta	1.21
Rel Volume	0.00
Avg Volume	318.18K
Volume	0

Perf Week	-7.49%
Perf Month	-10.70%
Perf Quarter	-13.65%
Perf Half Y	43.03%
Perf YTD	32.29%
Perf Year	21.06%
Perf 3Y	-90.43%
Perf 5Y	-92.74%
Perf 10Y	-97.81%
Recom	1.25
Target Price	29.50
Prev Close	15.69
Price	15.69
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-01-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-28-26	Initiated	Piper Sandler	Overweight	$35
Jan-21-26	Initiated	Guggenheim	Buy	$35
Aug-25-25	Initiated	Jefferies	Buy	$26
Aug-11-25	Initiated	H.C. Wainwright	Buy	$25
Jul-14-25	Initiated	Wedbush	Outperform	$27
Jun-25-25	Initiated	Stifel	Buy	$28
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight	$12
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Show Previous Ratings

Jun-26-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +9.24%
Jun-11-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Jun-02-26 04:15PM	Crescent Biopharma to Present at June Investor Conferences (GlobeNewswire) -13.77% +5.73%
May-29-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
May-21-26 05:30PM	Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (GlobeNewswire) +6.98%
04:30PM	Loading…
May-12-26 04:30PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +6.23%
May-06-26 07:30AM	Crescent Biopharma to Present at May Investor Conferences (GlobeNewswire)
Apr-29-26 04:15PM	Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -12.60% +6.83%
Apr-24-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Mar-27-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +12.30% +9.63%
Mar-06-26 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +6.53%
Feb-26-26 08:05AM	Crescent Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-23-26 07:30AM	Crescent Biopharma to Present at March Investor Conferences (GlobeNewswire)
Feb-19-26 07:30AM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +20.78%
07:30AM	Loading…
Feb-18-26 07:30AM	Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors (GlobeNewswire)
Feb-05-26 07:30AM	Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-30-26 04:05PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) -5.47%
Jan-05-26 07:00AM	Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors (GlobeNewswire)
Dec-18-25 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.) -7.97%
Dec-05-25 09:36AM	Crescent and Kelun-Biotech swap cancer asset rights in double deal (Pharmaceutical Technology)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 06:35AM	Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors (GlobeNewswire)
06:30AM	Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics (GlobeNewswire)
Nov-17-25 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
Nov-06-25 07:40AM	Crescent Biopharma: Q3 Earnings Snapshot (Associated Press Finance) +5.39%
07:30AM	Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:30AM	Crescent Biopharma to Present at November Investor Conferences (GlobeNewswire)
Nov-04-25 09:05AM	Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire)
07:30AM	Loading…
Aug-28-25 07:30AM	Crescent Biopharma to Present at September Investor Conferences (GlobeNewswire)
Jul-31-25 07:34AM	Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
07:32AM	Crescent Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
Jul-08-25 07:30AM	Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-05-25 04:01PM	GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals (Business Wire) -5.43%
May-14-25 07:02PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance) -5.50%
Apr-28-25 07:30AM	Crescent Biopharma Appoints David Lubner to Board of Directors (GlobeNewswire)
Apr-03-25 07:30AM	Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics (GlobeNewswire) -11.73%
Jan-14-25 09:34AM	GlycoMimetics and Crescent Biopharma Announce Merger Plans (TipRanks)
Nov-13-24 05:15PM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
Nov-12-24 08:00AM	Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 (PR Newswire) -5.29%
Nov-06-24 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting (Business Wire)
Oct-30-24 08:31AM	GlycoMimetics Announces Merger with Crescent Biopharma (TipRanks) -6.84%
Oct-29-24 07:00AM	GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma (Business Wire) +191.32%
06:30AM	GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint (Business Wire)
Jul-25-24 09:00AM	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan (Business Wire) -24.20%
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace) +13.89%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -12.60%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +25.28%
Jun-04-24 07:00AM	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire) +7.38%
May-29-24 04:01PM	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 (Business Wire) +6.82%
May-28-24 04:05AM	Pipeline Moves: Phase III AML trial fails to meet primary endpoint (Clinical Trials Arena)
May-09-24 10:58PM	GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 (InvestorPlace) -10.54%
07:19PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 07:42AM	Uproleselans failed Phase III AML trial shakes up GlycoMimetics future (Clinical Trials Arena)
May-07-24 05:21AM	GlycoMimetics reports data from Phase III AML treatment trial (Clinical Trials Arena)
May-06-24 03:53PM	Sector Update: Health Care Stocks Higher in Late Afternoon Trading (MT Newswires) -82.76%
12:45PM	GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint (MT Newswires)
08:40AM	Why Is GlycoMimetics (GLYC) Stock Down 77% Today? (InvestorPlace)
07:52AM	GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:00AM	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire)
Apr-25-24 07:00AM	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) -7.82%
Mar-28-24 10:12AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.66%
02:10AM	Q4 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 11:53AM	GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 (InvestorPlace) +11.58%
10:31AM	GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections (GuruFocus.com)
07:14AM	GlycoMimetics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
Mar-21-24 08:50AM	Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? (Zacks) -5.57%
Mar-13-24 07:00AM	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 (Business Wire)
Feb-26-24 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference (Business Wire) +5.52%
Feb-12-24 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jan-04-24 07:00AM	GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 (Business Wire)
Jan-03-24 07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +11.40%
Dec-10-23 12:00PM	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia (Business Wire)
Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-23 07:17AM	GlycoMimetics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 (Business Wire)
Jul-19-23 07:00AM	GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) -6.43%
Jul-13-23 09:29AM	12 Best Multibagger Penny Stocks To Buy (Insider Monkey)
Jun-26-23 08:00AM	GlycoMimetics Announces Its Addition to the Russell Microcap® Index (Business Wire)
Jun-15-23 08:00AM	GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Business Wire) +8.52%
Jun-12-23 11:13AM	We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-31-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 10:37AM	retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week (Simply Wall St.) -6.73%
May-03-23 10:17PM	Q1 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents) +7.35%
07:23AM	GlycoMimetics: Q1 Earnings Snapshot (AP Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 (Business Wire)
Apr-26-23 07:00AM	GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire)

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

CEO & DirectorMr. Joshua T. Brumm

President & COODr. Jonathan McNeill M.D.

Chief Medical OfficerDr. Ellie Im M.D.

Chief Financial OfficerMr. Richard William Scalzo M.B.A.

Senior VP of FinanceMr. Ryan Lynch

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynch Ryan	See Remarks	Jun 22 '26	Sale	17.99	465	8,365	13,871	Jun 23 04:04 PM
Pinkas Jan	Chief Scientific Officer	Jun 22 '26	Sale	17.99	1,288	23,171	22,239	Jun 23 04:04 PM
Scalzo Richard William	Chief Financial Officer	Jun 22 '26	Sale	17.99	1,112	20,005	20,298	Jun 23 04:03 PM
Bispham Barbara Harlin	See Remarks	Jun 22 '26	Sale	17.99	1,218	21,912	19,330	Jun 23 04:03 PM
Im Ellie Eunkyung	Chief Medical Officer	Jun 22 '26	Sale	17.99	1,219	21,930	22,069	Jun 23 04:02 PM
McNeill Jonathan	President and COO	Jun 22 '26	Sale	17.99	20,549	369,677	139,158	Jun 23 04:02 PM
Brumm Joshua T	Chief Executive Officer	Jun 22 '26	Sale	17.99	42,305	761,067	281,212	Jun 23 04:01 PM
Fairmount Funds Management LLC	Director	Dec 04 '25	Buy	13.41	1,360,000	18,237,600	2,747,866	Dec 08 04:30 PM

ORKA

Oruka Therapeutics Inc

SYRE

Spyre Therapeutics Inc

VRDN

Viridian Therapeutics Inc

ZBIO

Zenas Biopharma Inc

COGT

Cogent Biosciences Inc

APGE

Apogee Therapeutics Inc

CBIO

Crescent Biopharma Inc

Upgrade your Finviz experience